15.09 USD
↘ 13.40 (47.10%)AT CLOSE (03:59 PM EDT)
ArriVent BioPharma, Inc. Common Stock
AVBPNASDAQ • USD
14.97
↘ 0.13 (0.83%)
POST MARKET (AS OF 07:59 PM EDT)
Post Market
AS OF 07:59 PM EDT
14.97
↘ 0.13 (0.83%)
Market: CLOSED
AVBP is currently priced at $15.12. The stock presents a bearish profile across the board: technical indicators signal "Strong Sell" and our fundamental models agree with a "Sell" rating. Key drivers include a robust Altman Z-Score, a weak Piotroski F-Score of 0/9, negative Return on Equity and a bullish Golden Cross on the moving averages. On the valuation side, AVBP appears attractively valued relative to sector peers across key multiples.
Technical & fundamental data as of Oct 6, 2026.
Open?$12.09
High?$15.79
Low?$11.36
Prev. Close?$28.46
Volume?19.8M
Avg. Volume?1.2M
VWAP?$13.42
Rel. Volume?15.95x
Bid / Ask
Bid?$14.86 × 700
Ask?$15.00 × 100
Spread?$0.14
Midpoint?$14.93
Valuation & Ratios
Market Cap?744.1M
Shares Out?49.3M
Float?31.3M
Float %?67.3%
P/E Ratio?N/A
P/B Ratio?2.03
EPS?-$3.32
Dividend?0.00%
Ex-Dividend?N/A
News
Profile
ArriVent BioPharma Inc is a clinical-stage biopharmaceutical company dedicated to the identification, development, and commercialization of differentiated medicines to address the unmet medical needs of patients with cancers. The company focuses on advancing its lead product candidate, firmonertinib, for the treatment of epidermal growth factor receptor (EGFR) mutant non-small cell lung cancer (NSCLC), and developing a pipeline of novel therapeutics, including next-generation antibody-drug conjugates such as ARR-217 (MRG007), with an initial focus on solid tumors.
Address
18 CAMPUS BLVD.
NEWTOWN SQUARE, PA 19073-3269
Phone: 240-780-6356
NEWTOWN SQUARE, PA 19073-3269
Phone: 240-780-6356
Technical OutlookStrong Sell
Strong SellNeutralStrong Buy
Long-Term (Tide)?▼ Bearish(-2/3)
Medium-Term (Wave)?▼ Bearish(-2/3)
Short-Term (Ripple)?▼ Bearish(-3/3)
MA Alignment?Mixed
Full Technical Analysis →Fundamental OutlookSell
Strong SellNeutralStrong Buy
F-Score?3
Z-Score?100
Momentum?50
Short Sent.?10
Piotroski F-Score?0/9Weak
Altman Z-Score?13.89Safe
Confidence?48%Low
Short InterestSqueeze Risk
Short % of Float?27.97%Squeeze Risk
Short Interest?8.8M
Days to Cover?17.7
Free Float31.3M
Avg Daily Volume495.5K
Settlement Date2026-09-15
Financial Health
Current Ratio?14.16Strong
Quick Ratio?14.16Strong
Cash Ratio?5.56Strong
Debt/Equity?0.00Low
ValuationATTRACTIVELY VALUEDvs 1 peers + S&P 500
Score100/100
P/E?N/A▾
P/B?2.03CHEAP▾
Peers100
S&P73
P/S?N/A▾
P/FCF?N/A▾
EV/EBITDA?-3.3CHEAP▾
S&P97
EV/Sales?N/A▾
Returns & Efficiency
ROE?-44.6%WEAK▾
S&P3
ROA?-41.5%WEAK▾
S&P3
Cash Flow & Enterprise
FCF?N/A
Enterprise Value?$589.4M
Fundamentals ratios updated end of day